Trial Profile

A Phase II/III Study to Evaluate the Safety and Efficacy of BAT1308 Combined With Platinum-Based Chemotherapy ± Bevacizumab as First-Line Therapy For PD-L1-Positive (CPS ≥ 1) Persistent, Recurrent or Metastatic Cervical Cancer

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 17 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BAT 1308 (Primary) ; Bevacizumab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary)
Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Clear cell sarcoma; Renal cell carcinoma; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Bio-Thera Solutions

14 Apr 2025 According to Bio-Thera Solutions media release, data from this study will be presented at at the 2025 ASCO Annual Meeting
10 Feb 2025 Planned End Date changed from 1 Aug 2024 to 1 Jan 2027.
10 Feb 2025 Planned primary completion date changed from 1 Apr 2024 to 1 Sep 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com